(239 days)
Not Found
No
The document describes a cryosurgical system that uses nitrous oxide to ablate tissue. There is no mention of AI, ML, image processing, or any data analysis that would suggest the use of such technologies. The performance studies focus on clinical outcomes of the ablation procedure.
Yes
The device is described as a "cryosurgical tool" intended for "ablation of Barrett's Esophagus with high grade dysplasia" by "application of extreme cold to a 360° circumference, 90° circumference, or 45° circumference," which directly treats a medical condition.
No
Explanation: The device is described as a "cryosurgical tool" intended for "ablation", meaning it is used to destroy tissue. There is no mention of it being used to detect, diagnose, or monitor a medical condition.
No
The device description clearly outlines a system comprised of physical components: a Catheter, Handle, and Cartridge, which are used to deliver cryosurgical treatment. This is a hardware-based medical device.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for "cryosurgical tool in the field of general surgery, specifically for endoscopic applications, to include ablation of Barrett's Esophagus with high grade dysplasia." This describes a surgical procedure performed directly on the patient's tissue for therapeutic purposes (ablation).
- Device Description: The device description details a system that physically ablates tissue using extreme cold. It involves a catheter, handle, and cartridge, and is used in conjunction with an endoscope to deliver the cryotherapy directly to the target tissue.
- Lack of IVD Characteristics: An IVD is a medical device used to perform tests on samples taken from the human body (like blood, urine, tissue biopsies) to provide information for diagnosis, monitoring, or screening. This device does not perform any such tests on samples. It is a therapeutic device used to treat tissue in situ.
Therefore, the Coldplay CryoBalloon™ Ablation System is a therapeutic medical device, not an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The Coldplay CryoBalloon™ Focal Ablation System, Coldplay CryoBalloon™ Full Ablation System, and Coldplay CryoBalloon™ Swipe Ablation System are intended for use as a cryosurgical tool in the field of general surgery, specifically for endoscopic applications, to include ablation of Barrett's Esophagus with high grade dysplasia.
Product codes
GEH
Device Description
The subject device is a cryosurgical system with a nitrous oxide cooled balloon that is compatible with commercially available endoscopes with a minimum working channel inner diameter (ID) of 3.7 mm and length of 100 cm. The subject device is a system comprised of three components including a Catheter (sterile), Handle (nonsterile), and Cartridge (non-sterile).
The subject device is used to ablate unwanted tissue by application of extreme cold to a 360° circumference, 90° circumference, or 45° circumference and is identical to the respective Coldplay CryoBalloon™ Ablation System predicates. The balloon at the distal end of the Catheter comes in contact with tissue and is inflated with nitrous oxide. Tissue is visualized through the pre-inflated balloon, and the treatment site is selected by adjusting the endoscope and Handle. The nitrous oxide spray cools the balloon to ablate the unwanted tissue, and the nitrous oxide exhausts through the Handle.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Barrett's Esophagus
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
A clinical study was performed to support the modification of the indications for use to include ablation of Barrett's Esophagus with high grade dysplasia. The study conducted was prospective, multicenter clinical data for 37 patients with Barrett's Esophagus. There were a total of 56 focal ablations performed in 37 patients. For the 56 ablations performed, the duration of the ablation was 6 seconds (n=10), 8 seconds (n=28), or 10 seconds (n=18). No patients required any further interventions. Pain in the treatment area immediately post procedure was reported in 10 patients (27%) with median score of 2.5 (IQR 2-3). None of these patients required additional pain medication. At 2 days post-procedure, 5 patients (14%) reported pain in the treatment area with a median score of 4 (IQR 3-6) and pain when swallowing with median score of 4 (IQR 2-5). In the days following the ablation procedure, 3 patients (8%) used additional pain medication. There were no serious adverse events reported. At the time of follow-up endoscopy, full conversion of Barrett's epithelium to neosquamous epithelium was observed significantly more frequently in 6 (60%) of the 6second ablations, 23 (82%) of the 8-second ablations, and 18 (100%) of the 10second ablations (P=0.04). Conversion was confirmed through biopsy. During the follow-up period, no adverse events occurred. The clinical study results indicate, when used in accordance with the Instructions for Use, the subject device is effective at demonstrating complete response of high grade dysplasia at follow-up. The subject device prospective clinical study data and other published literature data indicate it is at least as safe and effective as the legally marketed predicates for ablation of Barrett's Esophagus with high grade dysplasia. The clinical performance data support the indication for use modification and the substantial equivalence determination.
Key Metrics
Not Found
Predicate Device(s)
K131523, K151054, K143625, K083737
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 878.4350 Cryosurgical unit and accessories.
(a)
Identification —(1)Cryosurgical unit with a liquid nitrogen cooled cryoprobe and accessories. A cryosurgical unit with a liquid nitrogen cooled cryoprobe and accessories is a device intended to destroy tissue during surgical procedures by applying extreme cold.(2)
Cryosurgical unit with a nitrous oxide cooled cryoprobe and accessories. A cryosurgical unit with a nitrous oxide cooled cryoprobe and accessories is a device intended to destroy tissue during surgical procedures, including urological applications, by applying extreme cold.(3)
Cryosurgical unit with a carbon dioxide cooled cryoprobe or a carbon dioxide dry ice applicator and accessories. A cryosurgical unit with a carbon dioxide cooled cryoprobe or a carbon dioxide dry ice applicator and accessories is a device intended to destroy tissue during surgical procedures by applying extreme cold. The device is intended to treat disease conditions such as tumors, skin cancers, acne scars, or hemangiomas (benign tumors consisting of newly formed blood vessels) and various benign or malignant gynecological conditions affecting vulvar, vaginal, or cervical tissue. The device is not intended for urological applications.(b)
Classification. Class II.
0
Image /page/0/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features a stylized caduceus symbol, which is a staff with two snakes coiled around it. To the left of the caduceus is the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged in a circular fashion.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
April 13, 2016
C2 Therapeutics, Inc. Ms. Theresa Brandner-Allen VP of Regulatory Affairs and Quality Assurance 303 Convention Way, Suite 1 Redwood City, California 94063
Re: K152329
Trade/Device Name: Coldplay Cryoballoon™ Focal Ablation System; Coldplay Cryoballoon™ Full Ablation System; Coldplay Cryoballoon™ Swipe Ablation System Regulation Number: 21 CFR 878.4350 Regulation Name: Cryogenic unit and accessories Regulatory Class: Class II Product Code: GEH Dated: March 07, 2016 Received: March 08, 2016
Dear Ms. Brandner-Allen:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21
1
CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its tollfree number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Jennifer R. Stevenson -A
For Binita S. Ashar, M.D., M.B.A., F.A.C.S. Director Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K152329
Device Name
Coldplay CryoBalloon™ Focal Ablation System, Coldplay CryoBalloon™ Full Ablation System, Coldplay CryoBalloon™ Swipe Ablation System
Indications for Use (Describe)
The Coldplay CryoBalloon™ Focal Ablation System, Coldplay CryoBalloon™ Full Ablation System, and Coldplay CryoBalloon™ Swipe Ablation System are intended for use as a cryosurgical tool in the field of general surgery, specifically for endoscopic applications, to include ablation of Barrett's Esophagus with high grade dysplasia.
Type of Use (Select one or both, as applicable)
| Prescription Use (Part 21 CFR 801 Subpart D) | |
|---|---|
| Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
K152329 510(k) Summary
This 510(k) summary is being submitted in accordance with the requirements of 21 CFR §807.92.
SUBMITTER I.
| Submitter Name: C2 Therapeutics, Inc. | |
|---|---|
| Address: | 303 Convention Way, Suite 1 |
| Redwood City, CA 94063 | |
| Phone Number: | 650-521-5921 |
| Fax Number: | 650-556-1145 |
| Contact Person: | Theresa Brandner-Allen |
| VP of Regulatory Affairs and Quality Assurance | |
| Date Prepared: | April 12, 2016 |
II. DEVICE
| Name of Device: | Coldplay CryoBalloon™ Focal Ablation System |
|---|---|
| Coldplay CryoBalloon™ Full Ablation System | |
| Coldplay CryoBalloon™ Swipe Ablation System |
Common Name: Cryosurgical Unit, Cryogenic Surgical Device
Classification Name: Cryosurgical Unit, Cryogenic Surgical Device 21 CFR§878.4350(a)(2)
Regulatory Class: Class II
Product Code: GEH
III. PREDICATE DEVICES
Coldplay CryoBalloon™ Ablation System: K131523, K151054 CSA Medical truFreeze: K143625 Barrx HALO: K083737
CSA Medical has reported two design-related recalls for the truFreeze device. Barrx Medical has reported three design-related recalls for the HALO device. The
4
Coldplay CryoBalloon™ Ablation System predicate devices have not been subject to a design-related recall.
IV. DEVICE DESCRIPTION
The subject device is a cryosurgical system with a nitrous oxide cooled balloon that is compatible with commercially available endoscopes with a minimum working channel inner diameter (ID) of 3.7 mm and length of 100 cm. The subject device is a system comprised of three components including a Catheter (sterile), Handle (nonsterile), and Cartridge (non-sterile).
The subject device is used to ablate unwanted tissue by application of extreme cold to a 360° circumference, 90° circumference, or 45° circumference and is identical to the respective Coldplay CryoBalloon™ Ablation System predicates. The balloon at the distal end of the Catheter comes in contact with tissue and is inflated with nitrous oxide. Tissue is visualized through the pre-inflated balloon, and the treatment site is selected by adjusting the endoscope and Handle. The nitrous oxide spray cools the balloon to ablate the unwanted tissue, and the nitrous oxide exhausts through the Handle.
INDICATIONS FOR USE V.
The Coldplay CryoBalloon™ Focal Ablation System, Coldplay CryoBalloon™ Full Ablation System, and Coldplay CryoBalloon™ Swipe Ablation System are intended for use as a cryosurgical tool in the field of general surgery, specifically for endoscopic applications, to include ablation of Barrett's Esophagus with high grade dysplasia.
VI. COMPARISON OF TECHNOLOGICAL CHARACTERISTICS WITH THE PREDICATE DEVICE
Cryoablation is the fundamental technological principle for both the subject Coldplay CryoBalloon™ Focal Ablation System. Coldplay CryoBalloon™ Full Ablation System, and Coldplay CryoBalloon™ Swipe Ablation System and the predicate Coldplay CryoBalloon™ Ablation Systems and the predicate CSA Medical truFreeze. Both the subject device and all predicate devices are used as endoscopic instrumentation for ablating unwanted tissue.
The only modification to the subject device is to update the labeling to modify the indication for use to list treatment of Barrett's Esophagus and to include the treatment parameters, similar to the indications for use and treatment parameter type updates made by the predicate devices and to reflect physician use. The subject device has similar technological characteristics to the legally marketed predicates. The subject device and predicate devices are based on the following same technological elements:
5
- . Inserted through an endoscope to access the treatment site
- . Apply extreme temperature (cryogen or heat) to ablate (freeze or cauterize) the unwanted tissue
- Use of a compliant balloon to position the treatment diffuser .
- User-controlled activation to release and apply the therapy ●
- . Software controlled
There have been no technological changes to the subject device, and there are no technological differences between the subject device and predicate devices. The subject device remains substantially equivalent to the predicate devices.
Per Section III, design-related recalls for the CSA Medical truFreeze predicate' 2 and Barrx Medical HALO predicate3,4,5 have been reported. The Coldplay CryoBalloon™ Ablation System predicate devices have not been subject to a designrelated recall.
VII. PERFORMANCE DATA
Because there have been no technological changes to the subject device, no additional bench testing, preclinical testing, sterilization, and biocompatibility testing was performed.
A clinical study was performed to support the modification of the indications for use to include ablation of Barrett's Esophagus with high grade dysplasia. The study conducted was prospective, multicenter clinical data for 37 patients with Barrett's Esophagus. There were a total of 56 focal ablations performed in 37 patients. For the 56 ablations performed, the duration of the ablation was 6 seconds (n=10), 8 seconds
1 Recall number Z-1513-2015 was conducted due to active and passive venting during the procedure. Because the Coldplay CryoBalloon Ablation System fully contains the cryogen during the procedure, active or passive venting is not required, and this design malfunction or potential patient injury is not relevant to the Coldplay CryoBalloon Ablation System. This recall has been terminated.
4 Recall number Z-0941-2015 was conducted due to an increase in complaint trending for a loss of audible sound associated with the timer. The software with audible sounder used in the Coldplay CryoBalloon Ablation System has been validated, and this design malfunction has not been observed with the Coldplay CryoBalloon Ablation System. This recall has been terminated.
3 Recall number Z-2745-2011 was conducted due device pivot mechanism's inability to return the electrode cap to a flat neutral position. Because the Coldplay CryoBalloon Ablation System's diffuser is fully contained within the balloon during the procedure, this design malfunction is not relevant to the Coldplay CryoBalloon Ablation System. This recall has been terminated.
4 Recall number Z-0192-2009 was conducted because some units may contain the wrong filter, which does not have the proper lock and may result in a leak. The Coldplay CryoBalloon System does not have a filter, and this design malfunction is not relevant to the Coldplay CryoBalloon Ablation System. This recall has been terminated. 3 Recall number Z-2379-2012 was conducted due to a potential failure of HALO Energy Generator to enter "stand by" mode when initially powered on prior to use on the patient. The software used in the Coldplay CryoBalloon
Ablation System has been validated, and this design malfunction has not been observed with the Coldplay CryoBalloon Ablation System. This recall has been terminated.
6
(n=28), or 10 seconds (n=18). No patients required any further interventions. Pain in the treatment area immediately post procedure was reported in 10 patients (27%) with median score of 2.5 (IQR 2-3). None of these patients required additional pain medication. At 2 days post-procedure, 5 patients (14%) reported pain in the treatment area with a median score of 4 (IQR 3-6) and pain when swallowing with median score of 4 (IQR 2-5). In the days following the ablation procedure, 3 patients (8%) used additional pain medication. There were no serious adverse events reported. At the time of follow-up endoscopy, full conversion of Barrett's epithelium to neosquamous epithelium was observed significantly more frequently in 6 (60%) of the 6second ablations, 23 (82%) of the 8-second ablations, and 18 (100%) of the 10second ablations (P=0.04). Conversion was confirmed through biopsy. During the follow-up period, no adverse events occurred. The clinical study results indicate, when used in accordance with the Instructions for Use, the subject device is effective at demonstrating complete response of high grade dysplasia at follow-up. The subject device prospective clinical study data and other published literature data indicate it is at least as safe and effective as the legally marketed predicates for ablation of Barrett's Esophagus with high grade dysplasia. The clinical performance data support the indication for use modification and the substantial equivalence determination.
VIII. CONCLUSION
The subject Coldplay CryoBalloon™ Focal Ablation System, Coldplay CryoBalloon™ Full Ablation System, and Coldplay CryoBalloon™ Swipe Ablation System are substantially equivalent to predicate devices. Use of the Coldplay CryoBalloon™ Focal Ablation System, Coldplay CryoBalloon™ Full Ablation System, and Coldplay CryoBalloon™ Swipe Ablation System for treatment of Barrett's Esophagus for ablation of high grade dysplasia is supported by a clinical study and performance data derived from literature.